Trans-Tasman Reg Structure Should Include Third-Party Review, Industry Says
This article was originally published in The Gray Sheet
Executive Summary
Industry will push for consideration of a third-party review system in upcoming stakeholder discussions on the creation of an Australia/New Zealand joint regulatory agency, according to Brian Vale, CEO of the Medical Industry Association of Australia (MIAA)
You may also be interested in...
Device Regulation Grows In Eastern Markets; Harmonization Has Far To Go
While medical device regulation is becoming increasingly common in developing overseas markets, harmonization is still "spotty," according to Carolyn Albertson, senior director of regulatory & global government affairs within Abbott's medical products group
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.